FN2 Earnings Intelligence
ResMed Inc. financials
ResMed Inc. (RMD) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 6/30/2022 | 6/30/2023 | 6/30/2024 | 6/30/2025 | 6/30/2026 | 6/30/2027 est. | 6/30/2028 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $273.7 | $227.9 | $238.4 | $1,209.4 | $1,469.2 | - | - |
| + Debt | $775.2 | $1,441.1 | $707.2 | $668.3 | $659.4 | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $3,578.1 | $4,223 | $4,685.3 | $5,146.3 | $5,653.4 | $5,809.7 | $6,184.5 |
| % Growth | 11.9% | 18.0% | 10.9% | 9.8% | 9.9% | 2.8% | 6.5% |
| Gross Profit | $2,024.3 | $2,355.7 | $2,655.3 | $3,055 | $3,451.7 | - | - |
| % Margin | 56.6% | 55.8% | 56.7% | 59.4% | 61.1% | - | - |
| EBITDA | $1,159.9 | $1,297 | $1,496.8 | $1,883.8 | $2,088.1 | - | - |
| % Margin | 32.4% | 30.7% | 31.9% | 36.6% | 36.9% | - | - |
| Net Income | $779.4 | $897.6 | $1,021 | $1,400.7 | $1,523.3 | - | - |
| % Margin | 21.8% | 21.3% | 21.8% | 27.2% | 26.9% | - | - |
| Diluted EPS | $5.30 | $6.09 | $6.92 | $9.51 | $10.43 | $12.09 | $13.30 |
| % Growth | 63.6% | 14.9% | 13.6% | 37.4% | 9.7% | 16.0% | 10.0% |
| Operating Cash Flow | $351.1 | $693.3 | $1,401.3 | $1,751.6 | $1,805.8 | - | - |
| CapEx | $134.8 | $119.7 | $99.5 | $89.9 | $156.3 | - | - |
| Free Cash Flow | $216.3 | $573.6 | $1,301.8 | $1,661.7 | $1,649.5 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 6/30/2022 | 6/30/2023 | 6/30/2024 | 6/30/2025 | 6/30/2026 | 6/30/2027 est. | 6/30/2028 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $3,578.1 | $4,223 | $4,685.3 | $5,146.3 | $5,653.4 | $5,809.7 | $6,184.5 |
| Gross Profit | $2,024.3 | $2,355.7 | $2,655.3 | $3,055 | $3,451.7 | - | - |
| EBITDA | $1,159.9 | $1,297 | $1,496.8 | $1,883.8 | $2,088.1 | - | - |
| Net Income | $779.4 | $897.6 | $1,021 | $1,400.7 | $1,523.3 | - | - |
| Diluted EPS | $5.30 | $6.09 | $6.92 | $9.51 | $10.43 | $12.09 | $13.30 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 6/30/2022 | 6/30/2023 | 6/30/2024 | 6/30/2025 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $273.7 | $227.9 | $238.4 | $1,209.4 | $1,469.2 |
| Short-term Debt | $9.9 | $9.9 | $9.9 | $9.9 | $260 |
| Long-term Debt | $765.3 | $1,431.2 | $697.3 | $658.4 | $399.4 |
| Total Debt | $775.2 | $1,441.1 | $707.2 | $668.3 | $659.4 |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 6/30/2022 | 6/30/2023 | 6/30/2024 | 6/30/2025 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $351.1 | $693.3 | $1,401.3 | $1,751.6 | $1,805.8 |
| Capital Expenditure | $134.8 | $119.7 | $99.5 | $89.9 | $156.3 |
| Free Cash Flow | $216.3 | $573.6 | $1,301.8 | $1,661.7 | $1,649.5 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 6/30/2022 | 6/30/2023 | 6/30/2024 | 6/30/2025 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | 11.9% | 18.0% | 10.9% | 9.8% | 9.9% |
| Gross Margin | 56.6% | 55.8% | 56.7% | 59.4% | 61.1% |
| EBITDA Margin | 32.4% | 30.7% | 31.9% | 36.6% | 36.9% |
| Net Margin | 21.8% | 21.3% | 21.8% | 27.2% | 26.9% |
| FCF Margin | 6.0% | 13.6% | 27.8% | 32.3% | 29.2% |
| Diluted EPS Growth | 63.6% | 14.9% | 13.6% | 37.4% | 9.7% |